YARTEMLEA is approved by the U.S. FDA for the treatment of TA-TMA in adults and in children ages two years and older. A marketing authorization application for YARTEMLEA for TA-TMA is under review by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback